**ALU 301-14 Endnotes & Bibliography**

**Endnotes**

1. Dec GW, Fuster V. 1994. Idiopathic dilated cardiomyopathy. N Engl J Med 331:1564-1575.
2. Mestroni L, Brun F, Spezzacatene A, Sinagra G, Taylor MR. Genetic causes of dilated cardiomyopathy. Prog Pediatr Cardiol. 2014 Dec;37:13-18.
3. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, Baughman KL, Kasper EK. 2000. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342:1077-1084.
4. Maron BJ; Gardin JM; Flack JM; Gidding SS; Kurosaki TT; Bild DE. 1995. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 92:785-789.
5. Maron BJ. 2002. Hypertrophic cardiomyopathy. A systematic review. JAMA 287:1308-1320.
6. Maron BJ, Sudden death in young athletes. N Engl J Med 2003;349:1064-75.
7. Spodick, DH. Pericardial disease. In: Heart Disease: A Textbook of Cardiovascular Medicine, Braunwald, E, Zipes, D, Libby, P (Eds), Saunders, New York 2001. p.183.
8. Troughton RW, Asher CR, Klein AL. 2004. Pericarditis. Lancet 363:717.
9. Hill EE, Herijgers P, Claus P. 2007. Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study. Eur Heart J 28:196.

## McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW, Jacobsen SJ, Redfield MM, Burnett JC. 2006. Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide. Biomarkers for Mortality in a Large Community-Based Cohort Free of Heart Failure. Hypertension 47:874.

1. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS. 2004. Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and Death. NEJM 350:655-663.
2. Illango RK 2007. Utilizing NT-ProBNP in the selection of risks for life insurance. J Insur Med 39:182–191.
3. Clark M, Kaufman V, Fulks M, Dolan VF, Stout RL.NT-proBNP as a predictor of all-cause mortality in a population of insurance applicants.J Insur Med. 2014;44(1):7-16.
4. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW 2005. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112:1825-1852.

**Selected Bibliography**

Iacovino JR. The non-mortality of hypertrophic cardiomyopathy in an unselected, community diagnosed and treated population. J Insur Med 1996; 28:51-4.

Illango RK 2007. Utilizing NT-ProBNP in the selection of risks for life insurance. J Insur Med 39:182–191.

Pokorski RJ. Effect of age on mortality experience in patients with hypertrophic cardiomyopathy. J Insur Med 1997; 29:43-8, Erratum in J Insur Med 1997; 29:157.

Pokorski RJ. Hypertrophic Cardiomyopathy: Risk factors for life and living benefits. J Insur Med 2002; 34:43-60.

Ten Cate FJ, Prognosis of hypertrophic cardiomyopathy. J Insur Med 1996; 28:42-45.

*Others*

ACC/ESC Clinical expert consensus document on hypertrophic cardiomyopathy, J Am Coll Cardiol 2003; 42:1688.

Autore C, Conte MR, Piccininno M et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardol 2002; 40:1864-9.

Bahler RC. Assessment of prognosis in idiopathic dilated cardiomyopathy. Chest 2002;121

Cannan CR, Reeder GS, Bailey KR et al. Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. Circulation 1995; 92:2488-2495.

Cecchi F, Olivotto I, Gistri R et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy N Engl J Med 2003; 349: 1027-35.

Coughlin SS, Neaton JD, Sengupta A et al. Predictors of mortality from idiopathic dilated cardiomyopathy in 356,222 men screened for the Multiple Risk Factor Intervention Trial. Am J Epidemiol 1994;139:166-72.

Coughlin SS, Tefft MC, Rice JC et al. Epidemiology of idiopathic dilated cardiomyopathy in the elderly: pooled results from two case-control studies. Am J Epidemiol 1996; 143:881-8.

Elliott PM, Gimeno Blanes JR, Mahon NG et al., Relation between severity of left ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001; 357:420-424.

Elliott PM, Poloniecki J, Dickie S et al. Sudden Death in Hypertrophic Cardiomyopathy: identification of high-risk patients. J Am Coll Cardiol 2000; 36:2212-8.

Eriksson MJ, Sinnenberg B, Woo A et al. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39:638-45.

Faris R, Coats AJS, Henein MY. Echocardiography-derived variables predict outcomes in patients with nonischemic dilated cardiomyopathy with or without a restrictive filling pattern. Am Heart J 2002; 144

Fauchier L, Babuty D, Poret P et al. Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy.

Fay WP, Taliercio CP, Istrup DM et al. Natural history of hypertrophic cardiomyopathy in the elderly. J Am Coll Cardiol 1990; 16:821-6.

Felker GM, Jaeger CJ, Klodas E et al. Myocarditis and long-term survival in peripartum cardiomyopathy. Am Heart J 2000; 140:785-91.

Felker GM, Thompson RE, Hare JM et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342:1077-84.

Kofflard MJM, Ten Cate FJ, van der Lee C et al. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol 2003; 41:987-93.

Marian AJ. On predictors of sudden cardiac death in hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 41:994-6.

Maron BJ, Casey SA, Hauser RG et al, Clinical course of hypertrophic cardiomyopathy with survival to advanced age. J Am Coll Cardiol 2003; 42:882-8.

Maron BJ, Olivotto I, Bellone P, et al. Clinical profile of stroke in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39:301-7.

Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death. Circulation 2000; 102:858-864.

Maron M, Olivotto I, Betocchi S et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348:295-303.

Nishimura RA, Holmes DR. Hypertrophic cardiomyopathy N Engl J Med 2004; 350:1320-7.

Olivotto I, Gistri R, Petrone P et al. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 41:315-21.

Olivotto I, Maron BJ, Cecchi F. Clinical significance of atrial fibrillation in hypertrophic cardiomyopathy. Curr Cardiol Rep 2001;3:141-6.

Shaw T Elliott P, McKenna WJ. Dilated cardiomyopathy: a genetically heterogeneous disease. Lancet 2002; 360:654-5.

Spirito P, Bellone P, Harris KM et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342:1778-85.